GEMINI

 
 

About Gemini

Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist. TLR4 stimulation with Gemini rebalances the innate immune response and has been demonstrated to have the potential to treat acute and chronic diseases associated with dysregulated inflammation.

We have conducted and completed preclinical, Phase 1, and Phase 1b studies and continue to advance Gemini towards FDA approval.

Revelation has conducted multiple preclinical studies demonstrating the therapeutic potential of Gemini in the target indications.

Revelation announced positive Phase 1 clinical data for intravenous treatment with Gemini. The primary safety endpoint was met in the Phase 1 study, and results demonstrated statistically significant pharmacodynamic activity as observed through expected changes in multiple biomarkers including upregulation of IL-10.

The Phase 1b PRIME study demonstrated that Gemini reduced damaging inflammation and corrected immunoparalysis for up to 7 days after a single dose. This correction of immunoparalysis demonstrates Gemini as a non-immunosuppressive agent. The reduction in active inflammation and restoration of immunocompetence supports the potential use of Gemini as an effective treatment for AKI and CKD.

Gemini is currently being evaluated as a potential treatment for acute kidney injury (GEM-AKI); Gemini is also being developed as a treatment for chronic kidney disease (GEM-CKD), as a treatment to reduce hyperinflammation and infection associated with severe burn (GEM-PBI), and as a treatment to prevent post-surgical infection (GEM-PSI). The potential of Gemini to correct dysregulated inflammation has been demonstrated in multiple preclinical models of AKI, CKD, and infection, as well as in two Phase 1 clinical studies.